Dihexa

Dihexa is a 4.0–4.5/10 fit for experimenters looking at cognition through a high-risk research-chemical lens, not people who want a normal nootropic, not a clinically proven memory drug. The cleanest evidence anchors are McCoy 2013, which supports rodent and cell procognitive activity, and Sun 2021, which reported APP/PS1 mouse memory rescue. FDA 2026 adds useful context: states human exposure data and key safety information are lacking. The practical gap is the same one that shows up across the report: mechanism and early outcomes are more convincing than broad real-world certainty. In practice, Dihexa belongs after the basics, works best when the target is specific, and deserves tracking around benefits, side effects, interactions, and cost before it becomes a standing protocol.

✅ Best for: Researchers and informed self-experimenters specifically studying neurodegenerative mechanisms, not general productivity seekers. The least-unreasonable use case would be a short, carefully documented cycle in someone with a specific cognitive or neurodegenerative hypothesis, medical oversight, third-party identity and purity testing, no cancer risk factors, no competitive-sport constraints, no pregnancy or pediatric exposure, and no prescription-medication complexity. Even then, dihexa is better framed as a research-risk decision than a supplement recommendation.

❌ Avoid if: You have any personal cancer history, strong family cancer predisposition, pregnancy, lactation, pediatric exposure, cardiovascular disease, active unexplained symptoms, or current prescription medications. Avoid dihexa if you compete in drug-tested sport because WADA's 2026 list covers HGF and growth-factor modulators even though dihexa is not named. Also avoid it if you want a normal nootropic stack. The evidence base is preclinical, dosing is unvalidated, sourcing is gray-market, and the safety downside is too large for casual use. Sourcing & dosing caveat: gray-market supply; score assumes clean, correctly-dosed material.